Results 211 to 220 of about 8,356 (237)
Some of the next articles are maybe not open access.
Effect of Brimonidine on Corneal Thickness
Journal of Ocular Pharmacology and Therapeutics, 2011Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication that is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors, there are only few studies available on the impact brimonidine has on the cornea ...
Torsten Schlote +3 more
openaire +3 more sources
Brimonidine tartrate for the treatment of glaucoma
Expert Opinion on Pharmacotherapy, 2018Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles, brimonidine is associated with high rates of ...
Judy L. Chen +3 more
openaire +3 more sources
A paradoxical ocular effect of brimonidine
American Journal of Ophthalmology, 2003We report an unusual paradoxical effect of brimonidine.Observational case report.A 70-year-old woman with bilateral normal tension glaucoma was treated with topical brimonidine and followed in an outpatient setting. The main outcome measured was intraocular pressure (IOP) in mm Hg.Brimonidine was observed to cause IOP elevation, confirmed on ...
Tim D. Matthews +2 more
openaire +3 more sources
Efficacy, safety, and current applications of brimonidine
Expert Opinion on Drug Safety, 2008The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and ...
L. Jay Katz +2 more
openaire +3 more sources
Evidence on the neuroprotective properties of brimonidine in glaucoma
2020glaucoma is the leading cause of irreversible blindness all over the world. The degree of visual field loss accounts for the severity of the disease and represents the main clinical outcome of treatment for patients affected by glaucoma. The α2 agonists, like brimonidine, emerged in the 1960s as topical ophthalmologic treatment.
Scuteri D. +6 more
openaire +5 more sources
Brimonidine for erythema caused by rosacea
Drug and Therapeutics Bulletin, 2014Brimonidine gel (Mirvaso—Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.
openaire +2 more sources
Charles Bonnet syndrome precipitated by brimonidine
Archivos de la Sociedad Española de Oftalmología (English Edition), 2013An 81-year-old woman with age-related macular degeneration and pseudoexfoliative glaucoma developed visual hallucinations (faces, flowers and frames) shortly after beginning brimonidine drops. Neurologic and psychiatric examination was normal. Visual hallucinations disappeared within 10 days after discontinuing the drug.The Charles Bonnet syndrome (CBS)
José Benítez-del-Castillo +6 more
openaire +3 more sources
Safety and efficacy of brimonidine in children with glaucoma
Journal of American Association for Pediatric Ophthalmology and Strabismus, 2001Brimonidine is a relatively selective alpha-agonist, which reduces intraocular pressure (IOP) by decreasing aqueous production and increasing uveoscleral outflow. Brimonidine passes through the blood-brain barrier, potentially causing central nervous system (CNS) toxicity. There have been reports of bradycardia, hypotension, hypothermia, hypotonia, and
Laura B. Enyedi, Sharon F. Freedman
openaire +3 more sources
Effects of 0.2% Brimonidine on Ocular Anterior Structures
Journal of Ocular Pharmacology and Therapeutics, 1999The aim of the study was to evaluate the effect of an alpha2-adrenergic agonist, 0.2% brimonidine, on a number of echobiometry and ultrasound biomicroscopy ocular parameters. Ten healthy subjects ranging in age from 20 to 40 years (mean age 29+/-3.39) were recruited into this prospective open-label trial.
Marchini G. +3 more
openaire +2 more sources
Uvéite antérieure et brimonidine
Journal Français d'Ophtalmologie, 2004Nous rapportons le cas d’un patient de 66 ans traite depuis 13 mois par brimonidine et presentant de facon bilaterale une uveite anterieure granulomateuse hypertensive associee a une allergie oculopalpebrale intense. Le bilan n’a retrouve aucune etiologie et l’evolution a ete rapidement favorable a l’arret de la brimonidine. Cette description montre qu’
L. Velasque +4 more
openaire +2 more sources